AI Article Synopsis
- Mutations in the MEN1 gene lead to multiple endocrine neoplasia syndrome type 1, causing issues like parathyroid hyperplasia and tumors in the pituitary and pancreas.
- Recent research shows that the MEN1 protein, menin, works with MLL family proteins in a histone methyltransferase complex to support tumor suppression.
- Menin helps regulate the expression of key cell cycle inhibitors p27Kip1 and p18Ink4c, and loss of menin or MLL function disrupts this regulation, promoting uncontrolled cell growth.
Article Abstract
Mutations in the MEN1 gene are associated with the multiple endocrine neoplasia syndrome type 1 (MEN1), which is characterized by parathyroid hyperplasia and tumors of the pituitary and pancreatic islets. The mechanism by which MEN1 acts as a tumor suppressor is unclear. We have recently shown that menin, the MEN1 protein product, interacts with mixed lineage leukemia (MLL) family proteins in a histone methyltransferase complex including Ash2, Rbbp5, and WDR5. Here, we show that menin directly regulates expression of the cyclin-dependent kinase inhibitors p27Kip1 and p18Ink4c. Menin activates transcription by means of a mechanism involving recruitment of MLL to the p27Kip1 and p18Ink4c promoters and coding regions. Loss of function of either MLL or menin results in down-regulation of p27Kip1 and p18Ink4c expression and deregulated cell growth. These findings suggest that regulation of cyclin-dependent kinase inhibitor transcription by cooperative interaction between menin and MLL plays a central role in menin's activity as a tumor suppressor.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC545577 | PMC |
| http://dx.doi.org/10.1073/pnas.0408836102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular markers in cell cycle visualisation during development and stress conditions in .
Quant Plant Biol
December 2024
Department of Biology, Howard University, Washington, DC, USA.
Plant growth and development are tightly regulated by cell division, elongation, and differentiation. A visible plant phenotype at the tissue or organ level is coordinated at the cellular level. Among these cellular regulations (cell division, elongation and differentiation), cell division in plants follows the same universal mechanisms across kingdoms of life, and involves conserved cell cycle regulatory proteins (cyclins, cyclin-dependent kinase and cell cycle inhibitors).
View Article and Find Full Text PDFOral selective estrogen receptor degraders for breast cancer treatment: focus on pharmacological differences.
Breast Cancer Res Treat
January 2025
Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology IRCCS, Milan, Italy.
Purpose: The management of hormone receptor-positive (HR +) breast cancer (BC) relies on endocrine therapy (ET), with a primary focus on disrupting estrogen receptor (ER) signaling due to its critical role in BC tumorigenesis and progression. While effective for both early-stage and advanced breast cancers, ET frequently encounters resistance mechanisms, including both ligand-dependent and ligand-independent trajectories, ultimately leading to disease progression.
Methods: We searched PubMed, EMBASE and Scopus databases to review the current evidence on the use of novel oral selective estrogen receptor degraders (SERDs) for the treatment of HR+ BC.
Improving Generalizability of Drug-Target Binding Prediction by Pre-trained Multi-view Molecular Representations.
Bioinformatics
January 2025
School of Information Science and Technology, Institute of Computational Biology, Northeast Normal University, Changchun, 130117, Jilin China.
Motivation: Most drugs start on their journey inside the body by binding the right target proteins. This is the reason that numerous efforts have been devoted to predicting the drug-target binding during drug development. However, the inherent diversity among molecular properties, coupled with limited training data availability, poses challenges to the accuracy and generalizability of these methods beyond their training domain.
View Article and Find Full Text PDFEffect of Cdk1 gene disruption on cell cycle progression in newt cells.
Dev Growth Differ
January 2025
Amphibian Research Center, Hiroshima University, Higashi-Hiroshima, Japan.
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression, in conjunction with cyclins. The cyclin-CDK system is highly conserved among eukaryotes, and CDK1 is considered essential for progression through the M phase. However, the extent to which cell cycle progression depends on CDK1 varies between cell types.
View Article and Find Full Text PDFAdjuvant endocrine therapy with cyclin-dependent kinase 4/6 inhibitor, ribociclib, for localized hormone receptor-positive/HER2- breast cancer (LEADER).
NPJ Breast Cancer
January 2025
Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib dosing schedules. Patients with stage I-III hormone receptor-positive (HR+)/HER2- breast cancer on adjuvant endocrine therapy (ET) were randomized to two ribociclib dosing schedules: 400 mg continuous vs 600 mg intermittent, with initiation in early (prior ET < 2 years) vs delayed (prior ET ≥ 2 years) setting.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!